| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Dec'16 | Sep'16 | Jun'16 | Mar'16 | Dec'15 | Sep'15 | Jun'15 | Mar'15 | Dec'14 | Sep'14 | Jun'14 | Mar'14 | Dec'13 | Sep'13 | Jun'13 | Mar'13 | Sep'12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | |||||||||||||||||||||||||||||
31,122 | 29,730 | 30,973 | 30,136 | 29,529 | 25,750 | 23,466 | 22,751 | 20,041 | 19,596 | 17,519 | 18,406 | 16,432 | 18,257 | 18,603 | 14,675 | 13,550 | 14,042 | 12,335 | 11,908 | 11,218 | 12,199 | 9,838 | 8,677 | 7,476 | 6,838 | 5,594 | 5,068 | 4,384 | 3,224 |
Operating expenses: | |||||||||||||||||||||||||||||
Cost of testing revenue | |||||||||||||||||||||||||||||
- | 9,673 | 9,114 | 8,777 | 8,513 | 8,704 | 8,261 | 8,246 | 7,867 | 7,769 | 7,169 | 6,960 | 6,297 | 6,515 | 6,367 | 6,301 | 6,279 | 6,174 | 5,618 | 5,139 | 4,566 | 4,865 | 4,168 | 3,966 | 3,607 | 3,471 | 3,132 | 3,231 | 2,773 | 1,984 |
Research and development | |||||||||||||||||||||||||||||
4,407 | 4,443 | 3,643 | 3,330 | 3,435 | 3,125 | 3,419 | 4,601 | 3,675 | 3,202 | 3,046 | 3,603 | 4,030 | 3,590 | 4,006 | 4,267 | 3,461 | 3,343 | 3,563 | 3,103 | 2,787 | 3,202 | 2,233 | 2,243 | 2,126 | 1,870 | 2,028 | 1,902 | 2,010 | 1,729 |
Selling and marketing | |||||||||||||||||||||||||||||
17,584 | 14,183 | 13,088 | 13,943 | 12,477 | 10,066 | 10,081 | 9,623 | 11,543 | 9,045 | 7,885 | 7,994 | 7,336 | 5,832 | 7,087 | 8,263 | 7,066 | 6,688 | 6,048 | 6,937 | 5,620 | 6,962 | 5,533 | 5,101 | 4,336 | 3,931 | 3,291 | 2,615 | 2,703 | 2,347 |
General and administrative | |||||||||||||||||||||||||||||
7,813 | 8,581 | 6,624 | 6,920 | 6,904 | 6,645 | 5,742 | 5,932 | 5,644 | 5,357 | 5,520 | 6,192 | 6,019 | 5,725 | 5,763 | 6,071 | 6,228 | 5,521 | 5,728 | 5,536 | 5,798 | 5,229 | 5,715 | 3,928 | 3,982 | 3,328 | 3,244 | 2,737 | 2,791 | 2,103 |
Intangible asset amortization | |||||||||||||||||||||||||||||
1,275 | 601 | 267 | 266 | 267 | 267 | 267 | 266 | 267 | 267 | 267 | 266 | 267 | 267 | 266 | 267 | 267 | - | 266 | 267 | - | - | - | - | - | - | - | - | - | - |
Total operating expenses | |||||||||||||||||||||||||||||
43,322 | 37,927 | 32,736 | 33,236 | 31,596 | 28,807 | 27,770 | 28,668 | 28,996 | 25,640 | 23,887 | 25,015 | 23,949 | 21,929 | 23,489 | 25,169 | 23,301 | 21,993 | 21,223 | 20,982 | 18,771 | 20,258 | 17,649 | 15,238 | 14,051 | 12,600 | 11,695 | 10,485 | 10,277 | 8,163 |
Loss from operations | |||||||||||||||||||||||||||||
-12,200 | -8,197 | -1,763 | -3,100 | -2,067 | -3,057 | -4,304 | -5,917 | -8,955 | -6,044 | -6,368 | -6,609 | -7,517 | -3,672 | -4,886 | -10,494 | -9,751 | -7,951 | -8,888 | -9,074 | -7,553 | -8,059 | -7,811 | -6,561 | -6,575 | -5,762 | -6,101 | -5,417 | -5,893 | -4,939 |
Interest expense | |||||||||||||||||||||||||||||
55 | 81 | 58 | 235 | 303 | 536 | 498 | 481 | 448 | 2,518 | 815 | 808 | 800 | 806 | 799 | 785 | 367 | 107 | 92 | 90 | 89 | 101 | 114 | 113 | 111 | - | 126 | 5 | - | - |
Other income, net | |||||||||||||||||||||||||||||
539 | 820 | 1,091 | 841 | 453 | 488 | 333 | 150 | 226 | 123 | 134 | 119 | 100 | 75 | 48 | 36 | 43 | 45 | 35 | 28 | 32 | 18 | 23 | 19 | 12 | -28 | -76 | -1,068 | -1,002 | 1 |
Net loss and comprehensive loss | |||||||||||||||||||||||||||||
-11,716 | -7,458 | -730 | -2,494 | -1,917 | -3,105 | -4,469 | -6,248 | -9,177 | -8,439 | -7,049 | -7,298 | -8,217 | -4,403 | -5,637 | -11,243 | -10,075 | -8,013 | -8,945 | -9,136 | -7,610 | -8,142 | -7,902 | -6,655 | -6,674 | -5,892 | -6,303 | -6,490 | -6,895 | -4,938 |
Comprehensive loss | |||||||||||||||||||||||||||||
-11,716 | -7,458 | -730 | -2,494 | -1,917 | -3,105 | -4,469 | -6,248 | -9,177 | -8,439 | -7,049 | -7,298 | -8,217 | -4,403 | -5,637 | -11,243 | -10,075 | -8,013 | -8,945 | -9,136 | -7,610 | -8,142 | -7,902 | -6,655 | -6,674 | - | -6,303 | - | - | - |
Net loss per common share, basic and diluted (in usd per share) | |||||||||||||||||||||||||||||
-0.24 | -0.15 | -0.02 | -0.05 | -0.05 | -0.05 | -0.12 | -0.18 | -0.27 | -0.24 | -0.21 | -0.22 | -0.24 | -0.13 | -0.20 | -0.40 | -0.36 | -0.29 | -0.32 | -0.35 | -0.34 | -0.36 | -0.37 | -0.31 | -0.32 | 17.01 | -6.59 | -7.53 | -9.04 | -7.49 |
Shares used to compute net loss per common share, basic and diluted (in shares) | |||||||||||||||||||||||||||||
49,792 | 49,209 | 48,588 | 45,586 | 41,168 | 40,875 | 38,620 | 34,314 | 34,271 | 34,058 | 33,946 | 33,873 | 33,823 | 31,727 | 27,916 | 27,859 | 27,817 | 27,747 | 27,640 | 26,048 | 22,539 | 22,523 | 21,648 | 21,237 | 21,148 | 14,053 | 955 | 861 | 763 | 659 |
Testing | |||||||||||||||||||||||||||||
Total Revenue | |||||||||||||||||||||||||||||
26,991 | - | - | - | 25,389 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of testing revenue | |||||||||||||||||||||||||||||
10,568 | - | - | - | 8,513 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Product | |||||||||||||||||||||||||||||
Total Revenue | |||||||||||||||||||||||||||||
3,409 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of testing revenue | |||||||||||||||||||||||||||||
1,559 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Biopharmaceutical | |||||||||||||||||||||||||||||
Total Revenue | |||||||||||||||||||||||||||||
722 | - | - | - | 4,140 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of testing revenue | |||||||||||||||||||||||||||||
116 | - | - | - | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |